Sales and marketing expenses for the quarter were $41 million compared to $36.8 million for the same period in 2025, primarily driven by higher personnel costs and higher sales-related travel expenses. Increases in personnel costs reflect a higher headcount driven by Salesforce expansion, as well as merit and annual inflationary wage adjustment for existing employees. Higher sales-related travel expenses reflect increased field activity to support growing test report volumes.

May 6, 2026 / receipt

Sales and marketing expenses for the quarter were $41 million compared to $36.8 million for the same period in 2025, primarily driven by higher personnel costs and higher sales-related travel expenses. Increases in personnel costs reflect a higher headcount driven by Salesforce expansion, as well as merit and annual inflationary wage adjustment for existing employees. Higher sales-related travel expenses reflect increased field activity to support growing test report volumes.

May 6, 2026 / receipt, needs a key / Frank Stokes, CFO | earnings call 2026-05-06 | transcript 3b78d5f0-cc1c-41c8-9eac-d4159f2e6df7 | chars 9996-10476 | segment 9

The increase is primarily driven by increased personnel costs due to both expanded headcount and compensation adjustments, higher expenses associated with training events and speaker conferences, and higher sales-related travel expenses.

Feb 26, 2026 / receipt, needs a key / Frank Stokes, CFO | earnings call 2026-02-26 | transcript 92f7b897-5bf0-4a4e-bf7d-e4179ab7c6c6 | chars 14930-15167 | segment 14

Sales and marketing expenses for the quarter were $32.8 million, compared to $29.8 million for the same period in 2024. This increase is mainly due to higher personnel costs, higher expenses associated with travel, and higher marketing expense.

Nov 3, 2025 / receipt, needs a key / Frank Stokes, CFO | earnings call 2025-11-03 | transcript 91a1da3c-dbcd-4025-8eae-f56c896f8316 | chars 15611-15855 | segment 14

The increase is mainly due to higher organizational and business development activities costs and higher sales-related travel expenses.

Aug 4, 2025 / receipt, needs a key / Frank Stokes, CFO | earnings call 2025-08-04 | transcript 2717d076-e852-4972-b454-0ee9dcfdc9a7 | chars 13888-14023 | segment 12

The increase is mainly due to higher personnel costs, higher organizational and business development activities costs, and higher sales-related travel and other expenses.

May 5, 2025 / receipt, needs a key / Frank Stokes, CFO | earnings call 2025-05-05 | transcript 9e3c9e00-52c9-4d34-bfea-4741822002d5 | chars 18248-18418 | segment 18

So part of our expectation here is to kind of watch and see how this most recent increase in territory size matures during the second quarter and then probably make additional expansion opportunities third and fourth quarter as we sort of see the relationships building among our expanded territories with the current customers and new customers so we don't expand too fast to go ahead and cause more disruption but expand at the right rate. And at the end of the day, I guess we should come back here is We aren't quite sure if in the 60 range is where we should be sitting, and part of that's looking at promotional responsiveness and territory sizes and travel time, but probably somewhere between 60s to 80s feels about right at full maturity.

Feb 27, 2025 / receipt, needs a key / Derek, CEO | earnings call 2025-02-27 | transcript a4a91eaf-f9ac-48bb-988d-3f96d98c179d | chars 34092-34839 | segment 34

The increase is mainly due to higher personnel costs, higher sales-related travel expense, and higher organizational and business development activities.

Feb 27, 2025 / receipt, needs a key / Frank Stokes, CFO | earnings call 2025-02-27 | transcript a4a91eaf-f9ac-48bb-988d-3f96d98c179d | chars 16146-16299 | segment 15

Sales and marketing expenses were $29.8 million in the third quarter of 2024, compared to $28.5 million for the same period in 2023. The increase is mainly due to higher travel and transportation costs incurred through our business development activities, as well as slightly higher marketing costs, while personnel costs were relatively consistent.

Nov 4, 2024 / receipt, needs a key / Frank Stokes, CFO | earnings call 2024-11-04 | transcript 834fb824-17bc-440b-b040-1abee73b25a9 | chars 14649-14998 | segment 15

The increase is mainly due to higher personnel costs and marketing expenses associated with travel, training events, and speaker conferences.

Aug 5, 2024 / receipt, needs a key / Frank Stokes, CFO | earnings call 2024-08-05 | transcript 37826b63-2f6f-4b67-b9d7-1e80642d9e03 | chars 13154-13295 | segment 12

The increase is mainly due to higher expense for training events and speaker conferences and expenses for salary and wages, partially offset by lower expense for travel and lower stock-based compensation expense.

May 2, 2024 / receipt, needs a key / Frank Stokes, CFO | earnings call 2024-05-02 | transcript 26f7e102-6ac3-44b3-90b4-6326793f3db2 | chars 14142-14354 | segment 13

The remainder of the increase in sales and marketing expenses was primarily associated with travel, training events, and conference fees.

May 3, 2023 / receipt, needs a key / Frank Stokes, CFO | earnings call 2023-05-03 | transcript 192ef5d7-b903-45ef-9641-a8b5bccc7e86 | chars 17527-17664 | segment 17

The remainder of the increase in sales and marketing expenses was primarily associated with travel, training events, and conference fees.

Feb 28, 2023 / receipt, needs a key / Frank, CFO | earnings call 2023-02-28 | transcript 8d14d8e6-5f97-42b5-a6bb-8bde1f1dc028 | chars 15793-15930 | segment 15

Castle Biosciences received a 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year

ir_statement / Sep 16, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 16, 2026 / receipt

Castle Biosciences received a 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year

ir_statement / Sep 16, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 16, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 16, 2026 / receipt

Castle Biosciences received a 2026 USA TODAY Top Workplaces USA Award for the fifth consecutive year

ir_statement / Sep 15, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 15, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 15, 2026 / receipt

Drive robust test volume growth

ir_statement / Sep 6, 2026 / receipt

Maintain strong Adjusted Gross Margin

ir_statement / Sep 6, 2026 / receipt

Both DecisionDx-Melanoma and TissueCypher achieved double digit year-over-year test volume growth, 16% and 58%, respectively, with March being a record month for both tests

ir_statement / Sep 6, 2026 / receipt

Total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 36% in 1Q26 year over year

ir_statement / Sep 6, 2026 / receipt